Nexus Pharmaceuticals, Inc. announced the launch of its new product line – Sterile Vials from Nexus Pharmaceuticals.
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- Nexus Pharmaceuticals, Inc. announced the launch of its new product line – Sterile Vials from Nexus Pharmaceuticals. The product trio includes 20mL clear vials, 10mL clear vials, and 2mL amber vials with plans to expand the portfolio with a wider range of sizes.
“This development aligns with Nexus’ commitment to innovation and represents a progressive step in broadening our healthcare scope and addressing supply chain constraints in the market,” said Omair Ahmed, Chief Operating Officer of Nexus Pharmaceuticals. “We have designed this product for use in various settings, including research laboratories, healthcare clinics, and veterinary offices. This direct-to-consumer offering is a new and exciting venture for us, and we look forward to a closer relationship with our customers.”
The sterilized vials are available for purchase in cartons consisting of twenty-five vials.
About Sterile Vials
Sterile Vials are manufactured in Nexus Pharmaceuticals’ state-of-the-art facility in Pleasant Prairie, Wisconsin. The 84,000 sq. ft. facility first opened its doors in 2021 with the mission of bringing pharmaceutical manufacturing back to the U.S.
The pyrogen-free glass vials are manufactured at an FDA-inspected facility under GMP conditions. They feature FluroTec® Barrier Film technology, providing an effective barrier against extractables and leachables and minimizing the risk of impurities, interactions, and medicine degradation. The finished vial stoppers are composed of a latex- and rubber-free chlorobutyl formulation.
About Nexus Pharmaceuticals, Inc.
Nexus Pharmaceuticals, Inc., a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals and its state-of-the-art manufacturing facility in Wisconsin, visit https://www.nexuspharma.net/project-tomorrow/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222006002/en/
Media Contact
Deana Mndrucic
dmndrucic@nexuspharma.net
847-996-3790
Source: Nexus Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20230222006002/en
